Along the same line, increased expression of TXNIP in On-treatment specimens was associated with decreased expression of the proliferation marker PCNA and lower proportion of Ki67-positive melanoma cells in 10 out of the 12 patient samples analyzed (Supp Fig. 1B–D). Here, PCNA is linked to melanoma.